

# John P Bilezikian

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3147245/john-p-bilezikian-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

299  
papers

26,369  
citations

84  
h-index

158  
g-index

335  
ext. papers

32,096  
ext. citations

7.9  
avg, IF

7.24  
L-index

#	Paper	IF	Citations
299	The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2022</b> , 1	10.5	1
298	Hypocalcemic Crisis: Acute Postoperative and Long-Term Management of Hypocalcemia <b>2022</b> , 113-124		
297	Osteoporosis in Men <b>2022</b> , 273-284		
296	Hungry bone syndrome following parathyroidectomy for primary hyperparathyroidism in a developed country in the Asia Pacific. A cohort study.. <i>Osteoporosis and Sarcopenia</i> , <b>2022</b> , 8, 11-16	2.3	
295	Post-acute COVID-19 syndrome. <i>Nature Medicine</i> , <b>2021</b> , 27, 601-615	50.5	976
294	DXA-Based Bone Strain Index: A New Tool to Evaluate Bone Quality in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2304-2312	5.6	2
293	Bone quality in hypoparathyroidism. <i>Minerva Endocrinology</i> , <b>2021</b> , 46, 325-334	2.5	
292	Bone Quality as Measured by Trabecular Bone Score in Normocalcemic Primary Hyperparathyroidism. <i>Endocrine Practice</i> , <b>2021</b> , 27, 992-997	3.2	1
291	Bone Mineral Density: Clinical Relevance and Quantitative Assessment. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 446-454	8.9	2
290	Association between fibroblast growth factor 23 and functional capacity among independent elderly individuals. <i>Einstein (Sao Paulo, Brazil)</i> , <b>2021</b> , 19, eAO5925	1.2	1
289	The skeletal actions of parathyroid hormone in primary hyperparathyroidism <b>2021</b> , 1159-1173		
288	Clinical Presentation of Hypoparathyroidism. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvab003	0.4	5
287	Primary Hyperparathyroidism: Pathophysiology, Surgical Indications, and Preoperative Workup <b>2021</b> , 486-493.e2		1
286	Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. <i>Endocrine</i> , <b>2021</b> , 71, 267-269		16
285	Clinical phenotypes of primary hyperparathyroidism in hospitalized patients who underwent parathyroidectomy. <i>Endocrine Connections</i> , <b>2021</b> , 10, 248-255	3.5	1
284	Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 297-316	10.5	3
283	Vertebral Fracture Assessment in Postmenopausal Women With Postsurgical Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 1303-1311	5.6	3

282	Rare Causes of Hypercalcemia: 2021 Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 3113-3128	5.6	8
281	Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 1201	10.5	5
280	Controversies in Vitamin D: A Statement From the Third International Conference. <i>JBMR Plus</i> , <b>2020</b> , 4, e10417	3.9	51
279	Report on the Audit on Burden of Osteoporosis in Eight Countries of the Eurasian Region: Armenia, Belarus, Georgia, Moldova, Kazakhstan, the Kyrgyz Republic, the Russian Federation, and Uzbekistan. <i>Archives of Osteoporosis</i> , <b>2020</b> , 15, 175	2.9	3
278	Hypomagnesuria is Associated With Nephrolithiasis in Patients With Asymptomatic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	2
277	Non-surgical management of primary hyperparathyroidism in the aging population. <i>Maturitas</i> , <b>2020</b> , 136, 49-53	5	1
276	Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1-84) Therapy in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , <b>2020</b> , 35, 1274-1281	6.3	6
275	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , <b>2020</b> , 26, 1017-1032	50.5	1253
274	MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. <i>European Journal of Endocrinology</i> , <b>2020</b> , 183, R133-R147	6.5	143
273	Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?. <i>Archives of Endocrinology and Metabolism</i> , <b>2020</b> , 64, 331-336	2.2	3
272	Treatment with Parathyroid Hormone <b>2020</b> , 25-31		
271	PTH and PTHrP Analogs: Treatment of Osteoporosis. <i>Contemporary Endocrinology</i> , <b>2020</b> , 349-362	0.3	
270	Clinical and translational pharmacology of bisphosphonates <b>2020</b> , 1671-1687		
269	Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	14
268	Pharmacologic mechanisms of therapeutics <b>2020</b> , 1633-1642		0
267	Drugs acting on the calcium receptor <b>2020</b> , 1657-1670		
266	Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2020</b> , 1	10.5	5
265	Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	9

264	A Simple Formula to Estimate Parathyroid Weight on 4D-CT, Predict Pathologic Weight, and Diagnose Parathyroid Adenoma in Patients with Primary Hyperparathyroidism. <i>American Journal of Neuroradiology</i> , <b>2020</b> , 41, 1690-1697	4.4	4
263	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 1861-1872	2.5	3
262	Osteitis Fibrosa Cystica. <i>JBMR Plus</i> , <b>2020</b> , 4, e10403	3.9	1
261	Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	35
260	Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	22
259	Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5136-5147	5.6	23
258	Vitamin D supplementation and musculoskeletal health. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 85-86	18.1	12
257	Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2748-2756	5.6	25
256	Three generational phenotypes of sporadic primary hyperparathyroidism: evolution defined by technology. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 745-747	18.1	9
255	Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism. <i>Radiology</i> , <b>2019</b> , 291, 469-476	20.5	59
254	Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5601-5610	5.6	28
253	Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 2097-2102	2.5	11
252	Trabecular bone score: a useful clinical tool for the evaluation of skeletal health in women of short stature. <i>Endocrine</i> , <b>2019</b> , 66, 398-404	4	1
251	Update on hypoparathyroidism. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 381-387	5.3	6
250	Osteoanabolic and dual action drugs. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1084-1094	3.8	16
249	Pharmacology of bisphosphonates. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1052-1062	3.8	59
248	Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. <i>Endocrine Reviews</i> , <b>2019</b> , 40, 1109-1151	27.2	304
247	Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 196-205	5.6	33

246	Pre-operative localization of abnormal parathyroid tissue by Tc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency. <i>Endocrine</i> , <b>2018</b> , 60, 36-45	4	6
245	Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 722-731	5.6	39
244	Primary hyperparathyroidism: recent advances. <i>Current Opinion in Rheumatology</i> , <b>2018</b> , 30, 427-439	5.3	17
243	Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 1512-1521	5.6	20
242	Primary hyperparathyroidism [Hypercalcemic and normocalcemic variants. <i>Current Opinion in Endocrine and Metabolic Research</i> , <b>2018</b> , 3, 42-50	1.7	1
241	New and developing pharmacotherapy for osteoporosis in men. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 253-264	4	15
240	Stop the war on DXA!. <i>Annals of the New York Academy of Sciences</i> , <b>2018</b> , 1433, 12-17	6.5	6
239	Brown tumors of primary hyperparathyroidism may be a source of extrarenal 1,25-dihydroxyvitamin D production. <i>Endocrine</i> , <b>2018</b> , 60, 524-527	4	
238	Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 252-267	3.8	24
237	Hyperparathyroidism. <i>Lancet, The</i> , <b>2018</b> , 391, 168-178	40	224
236	Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 2132-2139	6.3	10
235	ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2949-2957	5.6	90
234	AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. <i>Head and Neck</i> , <b>2018</b> , 40, 1617-1629	4.2	22
233	Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 1900-1901	6.3	0
232	Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab. <i>Osteoporosis and Bone Diseases</i> , <b>2018</b> , 21, 17-22	0.8	11
231	Initiation of dapagliflozin and treatment-emergent fractures. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1070-1074	6.7	26
230	Primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 32, 593-607	6.5	46
229	Management of normocalcemic primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 32, 837-845	6.5	33

228	Primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 101247	6.5	8
227	The Epidemiology of Osteoporotic Fractures <b>2018</b> , 398-404		3
226	New Directions in Treatment of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2018</b> , 47, 901-915	5.5	7
225	Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 3993-4004	5.6	117
224	Sarcopenia and Osteoporosis <b>2018</b> , 498-504		
223	Trabecular Bone Score <b>2018</b> , 277-286		1
222	Biochemical Markers of Bone Turnover in Osteoporosis <b>2018</b> , 293-301		0
221	Osteoblasts <b>2018</b> , 31-37		6
220	Adverse Effects of Drugs for Osteoporosis <b>2018</b> , 579-587		
219	Hypocalcemia <b>2018</b> , 646-653		2
218	Signs and Symptoms of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2018</b> , 47, 759-770	5.5	22
217	Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2194-2207	3.8	120
216	The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 1931-1939	6.3	20
215	Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. <i>Cell Metabolism</i> , <b>2017</b> , 25, 661-672	24.6	208
214	Romozosumab for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 255-263	3.4	52
213	Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 200-210	6.4	96
212	Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. <i>Endocrine</i> , <b>2017</b> , 55, 273-282	4	32
211	Novel Therapies for Postmenopausal Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2017</b> , 46, 207-219	5.5	20

210	Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25- $\mu$ g or 50- $\mu$ g Daily Doses. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 2096-2102	3.5	12
209	Hypoparathyroidism. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17055	51.1	100
208	Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism. <i>Endocrine</i> , <b>2017</b> , 58, 380-385	4	38
207	Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. <i>Endocrine</i> , <b>2017</b> , 55, 591-598	4	35
206	Sclerostin measurement in human disease: Validity and current limitations. <i>Bone</i> , <b>2017</b> , 96, 24-28	4.7	15
205	Primary Hyperparathyroidism; Current Management Guidelines <b>2017</b> , 331-341		
204	Stress Fractures: Concepts and Therapeutics. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 525-534	5.6	26
203	Primary hyperparathyroidism. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16033	51.1	113
202	Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 308-16	6.3	48
201	Management of Hypoparathyroidism: Present and Future. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2313-24	5.6	103
200	Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2742-50	5.6	75
199	Precision of Digital Topological Skeletonization Based Individual Trabecula Segmentation (ITS) Analysis of Trabecular Microstructure at the Distal Radius and Tibia by HR-pQCT. <i>Pattern Recognition Letters</i> , <b>2016</b> , 76, 83-89	4.7	6
198	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 44-51	5.6	176
197	Management of Hypoparathyroidism: Summary Statement and Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2273-83	5.6	207
196	Presentation of Hypoparathyroidism: Etiologies and Clinical Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2300-12	5.6	175
195	Epidemiology and Diagnosis of Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2284-99	5.6	148
194	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 157-66	5.6	290
193	Primary Hyperparathyroidism. <i>F1000Research</i> , <b>2016</b> , 5,	3.6	37

192	Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial. <i>Archives of Endocrinology and Metabolism</i> , <b>2016</b> , 60, 54-9	2.2	8
191	Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1082-8	6.3	13
190	BEYOND DXA: ADVANCES IN CLINICAL APPLICATIONS OF NEW BONE IMAGING TECHNOLOGY. <i>Endocrine Practice</i> , <b>2016</b> , 22, 990-8	3.2	10
189	Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 681-9	5.5	27
188	PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 180-9	6.3	21
187	Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. <i>European Journal of Endocrinology</i> , <b>2015</b> , 172, 527-35	6.5	41
186	PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2015</b> , 10, 5-13	4.1	15
185	Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1309-15	5.6	89
184	How Long to Treat with Denosumab. <i>Current Osteoporosis Reports</i> , <b>2015</b> , 13, 415-20	5.4	6
183	Bone Histomorphometry and Bone Quality in Primary Hyperparathyroidism <b>2015</b> , 429-445		5
182	Bone Turnover Markers in Primary Hyperparathyroidism <b>2015</b> , 423-428		1
181	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism <b>2015</b> , 489-497		
180	Anabolic and Catabolic Pathways of Parathyroid Hormone on the Skeleton <b>2015</b> , 233-244		1
179	Skeletal Manifestations of Hypoparathyroidism <b>2015</b> , 771-779		1
178	Asymptomatic Primary Hyperparathyroidism <b>2015</b> , 317-330		2
177	Normocalcemic PHPT <b>2015</b> , 331-339		5
176	Parathyroid hormone therapy for hypoparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 29, 47-55	6.5	21
175	The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2015</b> , 24, 324-9	3.5	7



174	Spontaneous Remission of Primary Hyperparathyroidism Related to an Autoimmune Disease: A Case Report. <i>AACE Clinical Case Reports</i> , <b>2015</b> , 1, e255-e259	0.7	1
173	Hypoglycemia Secondary to Sulfonylurea Ingestion in a Patient with End Stage Renal Disease: Results from a 72-Hour Fast. <i>Case Reports in Endocrinology</i> , <b>2015</b> , 2015, 742781	1.2	2
172	Parathyroid hormone: anabolic and catabolic actions on the skeleton. <i>Current Opinion in Pharmacology</i> , <b>2015</b> , 22, 41-50	5.1	251
171	Skeletal Imaging in Primary Hyperparathyroidism <b>2015</b> , 447-454		3
170	Primary hyperparathyroidism: Rheumatologic manifestations and bone disease <b>2015</b> , 1688-1691		
169	Replacement Therapy with PTH(184) <b>2015</b> , 333-342		
168	Trabecular bone score: a noninvasive analytical method based upon the DXA image. <i>Journal of Bone and Mineral Research</i> , <b>2014</b> , 29, 518-30	6.3	456
167	Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3580-94	5.6	227
166	Update on romosozumab : a humanized monoclonal antibody to sclerostin. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 697-707	5.4	26
165	Bone density testing: science, the media, and patient care. <i>Current Osteoporosis Reports</i> , <b>2014</b> , 12, 227-9	5.4	6
164	Utility of the trabecular bone score (TBS) in secondary osteoporosis. <i>Endocrine</i> , <b>2014</b> , 47, 435-48	4	96
163	Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3561-9	5.6	778
162	Differing effects of denosumab and alendronate on cortical and trabecular bone. <i>Bone</i> , <b>2014</b> , 59, 173-9	4.7	118
161	Trabecular bone score: perspectives of an imaging technology coming of age. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2014</b> , 58, 493-503		37
160	New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. <i>Bone Research</i> , <b>2014</b> , 2, 14043	13.3	5
159	Bone disease in primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2014</b> , 58, 553-61		84
158	Bone markers and osteoporosis therapy. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2014</b> , 58, 504-13		21
157	Hospital care for primary hyperparathyroidism in Italy: a 6-year register-based study. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 481-7	6.5	7

156	PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3694-9	5.6	79
155	Parathyroid hormone in the evaluation of hypercalcemia. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2680-1	27.4	9
154	Parathyroid hormone 1-84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, E2025-8	5.6	4
153	Osteoporosis in Men <b>2014</b> , 323-333		1
152	Combination therapy with risedronate and teriparatide in male osteoporosis. <i>Endocrine</i> , <b>2013</b> , 44, 237-46		53
151	Asymptomatic primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 14-21	3.5	65
150	New Approaches to Osteoporosis Therapeutics <b>2013</b> , 1963-1985		
149	The effect of PTH(1-84) on quality of life in hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 2356-61	5.6	138
148	Idiopathic osteoporosis in men. <i>Current Osteoporosis Reports</i> , <b>2013</b> , 11, 286-98	5.4	15
147	Recovery of parathyroid hormone secretion and function in postoperative hypoparathyroidism: a case series. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 4285-90	5.6	15
146	New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. <i>Bone</i> , <b>2013</b> , 55, 57-63	4.7	58
145	Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , <b>2013</b> , 1, 275-83	18.1	181
144	Bone turnover markers in primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 22-7	3.5	28
143	Normocalcemic primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 33-9	3.5	112
142	Trabecular bone score is associated with volumetric bone density and microarchitecture as assessed by central QCT and HRpQCT in Chinese American and white women. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 554-61	3.5	56
141	Osteoporosis update from the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 584-600	3.5	3
140	Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 137-44	5.6	101
139	Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 1519-28	5.6	79

138	Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 4736-43	5.6	20
137	Osteoporosis: what's new and on the horizon. <i>Clinical Obstetrics and Gynecology</i> , <b>2013</b> , 56, 730-8	1.7	4
136	The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism and in Osteoporosis <b>2013</b> , 1249-1265		
135	Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 1029-40	6.3	133
134	Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 2734-41	5.6	88
133	Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. <i>Bone Research</i> , <b>2013</b> , 1, 162-9	13.3	29
132	Diagnosis and management of primary hyperparathyroidism--a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2013</b> , 57, 406-24		42
131	Effect of renal function on skeletal health in primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 1501-7	5.6	29
130	Combination anabolic and antiresorptive therapy for osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2012</b> , 41, 643-54	5.5	17
129	Safety of osteoanabolic therapy: a decade of experience. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 2419-28	6.3	109
128	Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. <i>Journal of Drug Assessment</i> , <b>2012</b> , 1, 11-9	1.5	4
127	Patient-specific bone modelling and remodelling simulation of hypoparathyroidism based on human iliac crest biopsies. <i>Journal of Biomechanics</i> , <b>2012</b> , 45, 2411-6	2.9	25
126	Osteoporosis in men: an Endocrine Society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 1802-22	5.6	370
125	More bone density testing is needed, not less. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 739-42	6.3	25
124	Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 2990-3011	5.6	830
123	Sclerostin: therapeutic horizons based upon its actions. <i>Current Osteoporosis Reports</i> , <b>2012</b> , 10, 64-72	5.4	55
122	Mini-review: new therapeutic options in hypoparathyroidism. <i>Endocrine</i> , <b>2012</b> , 41, 410-4	4	24
121	Primary hyperparathyroidism. <i>Endocrine Practice</i> , <b>2012</b> , 18, 781-90	3.2	30

120	Osteoporosis update from the 2010 santa fe bone symposium. <i>Journal of Clinical Densitometry</i> , <b>2011</b> , 14, 1-21	3.5	8
119	Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. <i>Nature Reviews Rheumatology</i> , <b>2011</b> , 7, 447-56	8.1	187
118	New approaches to the treatment of osteoporosis. <i>Annual Review of Medicine</i> , <b>2011</b> , 62, 307-22	17.4	34
117	Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. <i>Bone</i> , <b>2011</b> , 48, 557-61	4.7	53
116	Therapy of osteoporosis in men with teriparatide. <i>Journal of Osteoporosis</i> , <b>2011</b> , 2011, 463675	2.8	16
115	Lawrence G. Raisz November 13, 1925-August 25, 2010. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 903-11	6.3	1
114	Better skeletal microstructure confers greater mechanical advantages in Chinese-American women versus white women. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 1783-92	6.3	71
113	PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 2727-36	6.3	104
112	Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 2317-37	6.3	369
111	Circulating sclerostin in disorders of parathyroid gland function. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 3804-10	5.6	61
110	Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2010</b> , 54, 220-6		38
109	Teriparatide: Variations on the theme of a 2-year therapeutic course. <i>IBMS BoneKEy</i> , <b>2010</b> , 7, 84-87		6
108	2009 Santa Fe Bone symposium. <i>Journal of Clinical Densitometry</i> , <b>2010</b> , 13, 1-9	3.5	6
107	Three dimensional cancellous bone structure in hypoparathyroidism. <i>Bone</i> , <b>2010</b> , 46, 190-5	4.7	71
106	High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 746-56	6.3	134
105	Normocalcemic primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2010</b> , 54, 106-9		74
104	Primary Hyperparathyroidism in Men <b>2010</b> , 465-478		
103	Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines. <i>Endocrine Practice</i> , <b>2009</b> , 15, 494-8	3.2	10

102	Alendronate therapy in men with primary hyperparathyroidism. <i>Endocrine Practice</i> , <b>2009</b> , 15, 705-13	3.2	38
101	Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2306-12	5.6	134
100	Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2766-72	5.6	111
99	Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. <i>American Journal of Medicine</i> , <b>2009</b> , 122, S14-21	2.4	117
98	The official positions of the International Society for Clinical Densitometry: perceptions and commentary. <i>Journal of Clinical Densitometry</i> , <b>2009</b> , 12, 267-71	3.5	24
97	Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 335-9	5.6	660
96	Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. <i>Journal of Clinical Densitometry</i> , <b>2008</b> , 11, 75-91	3.5	344
95	Racial differences in bone density and fracture risk in the United States. <i>International Journal of Rheumatic Diseases</i> , <b>2008</b> , 11, 341-346	2.3	8
94	Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 3484-9	5.6	20
93	Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration. <i>Endocrinology</i> , <b>2008</b> , 149, 5713-23	4.8	60
92	The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 3462-70	5.6	401
91	Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 3785-93	5.6	170
90	Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. <i>Current Osteoporosis Reports</i> , <b>2008</b> , 6, 24-30	5.4	87
89	The cell biology of parathyroid hormone in osteoblasts. <i>Current Osteoporosis Reports</i> , <b>2008</b> , 6, 72-6	5.4	67
88	Parathyroid hormone and the cardiovascular system. <i>Current Osteoporosis Reports</i> , <b>2008</b> , 6, 77-83	5.4	90
87	Osteoporosis in men: Pathophysiology and treatment. <i>Current Sexual Health Reports</i> , <b>2008</b> , 5, 83-89	1.2	
86	Dynamic and structural properties of the skeleton in hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 2018-24	6.3	141
85	Parathyroid carcinoma. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 1869-80	6.3	125

84	Osteoporosis in men. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2007</b> , 36, 399-419	5.5	74
83	New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. <i>Journal of Bone and Mineral Research</i> , <b>2007</b> , 22, 717-23	6.3	63
82	Osteoporosis in men: pathophysiology and treatment. <i>Current Osteoporosis Reports</i> , <b>2007</b> , 5, 22-8	5.4	5
81	Osteoporosis in men: pathophysiology and treatment. <i>Current Rheumatology Reports</i> , <b>2007</b> , 9, 71-7	4.9	8
80	Mechanisms of anabolic therapies for osteoporosis. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 905-16	59.2	490
79	Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 3535-41	5.6	50
78	Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 3114-21	5.6	271
77	Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 942-7	5.6	22
76	Anabolic therapy for osteoporosis. <i>Women's Health</i> , <b>2007</b> , 3, 243-53	3	6
75	An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 1470-6	5.5	73
74	Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2007</b> , 51, 1404-12		20
73	The use of parathyroid hormone in the treatment of osteoporosis. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2006</b> , 7, 113-21	10.5	102
72	Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. <i>Current Osteoporosis Reports</i> , <b>2006</b> , 4, 5-13	5.4	20
71	Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2006</b> , 1, 281-295	4.1	5
70	Glucocorticoid-induced osteoporosis: an update. <i>Trends in Endocrinology and Metabolism</i> , <b>2006</b> , 17, 144-8	8.8	260
69	Asymptomatic primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2006</b> , 50, 647-56		16
68	Parathyroid hormone as an anabolic skeletal therapy. <i>Drugs</i> , <b>2005</b> , 65, 2481-98	12.1	64
67	One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 555-65	59.2	477

66	Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. <i>European Journal of Endocrinology</i> , <b>2005</b> , 152, 199-205	6.5	57
65	Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 135-41	5.6	349
64	Arterial stiffness in mild primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 3326-30	5.6	112
63	Anabolic therapy for osteoporosis. <i>International Journal of Fertility and Women's Medicine</i> , <b>2005</b> , 50, 53-60		5
62	Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 3319-25	5.6	204
61	Aromatase activity and bone homeostasis in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 5898-907	5.6	142
60	The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. <i>Osteoporosis International</i> , <b>2004</b> , 15, 992-7	5.3	138
59	Clinical practice. Asymptomatic primary hyperparathyroidism. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 1746-51	59.2	269
58	Asymptomatic primary hyperparathyroidism: a medical perspective. <i>Surgical Clinics of North America</i> , <b>2004</b> , 84, 787-801	4	27
57	Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: a prospective analysis of the NHANES I follow-up study. <i>American Journal of Medicine</i> , <b>2004</b> , 117, 169-74	2.4	56
56	The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 5644-9	5.6	193
55	"Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 5348-52	5.6	144
54	Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 1150-6	5.6	212
53	Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 4725-30	5.6	76
52	Bone strength in primary hyperparathyroidism. <i>Osteoporosis International</i> , <b>2003</b> , 14 Suppl 5, S113-5; discussion S115-7	5.3	34
51	New anabolic therapies in osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2003</b> , 32, 285-307	5.5	49
50	The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1207-15	59.2	991
49	The anabolic effects of parathyroid hormone therapy. <i>Clinics in Geriatric Medicine</i> , <b>2003</b> , 19, 415-32	3.8	81

48	When should a gynecologist refer a patient for specialty care in osteoporosis?. <i>International Journal of Fertility and Women's Medicine</i> , <b>2003</b> , 48, 132-6; discussion 137-8		
47	Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 4033-41	5.6	148
46	Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 5353-61	5.6	462
45	Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. <i>Journal of Bone and Mineral Research</i> , <b>2002</b> , 17 Suppl 2, N2-11	6.3	35
44	Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the future. <i>Journal of Bone and Mineral Research</i> , <b>2002</b> , 17 Suppl 2, N57-67	6.3	13
43	Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. <i>Journal of Bone and Mineral Research</i> , <b>2001</b> , 16, 1846-53	6.3	495
42	Clinical review 123: Anabolic therapy for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 957-64	5.6	157
41	Tc99m-sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 5138-41	5.6	20
40	Clinical spectrum of primary hyperparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2000</b> , 1, 237-45	10.5	50
39	Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 3069-76	5.6	280
38	Osteoporosis in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 3431-4	5.6	170
37	A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 1249-55	59.2	719
36	The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. <i>American Journal of Medicine</i> , <b>1999</b> , 107, 561-7	2.4	187
35	Intracellular Ca <sup>2+</sup> homeostasis in trypomastigotes of <i>Trypanosoma cruzi</i> . <i>Journal of Eukaryotic Microbiology</i> , <b>1998</b> , 45, 80-6	3.6	6
34	Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 599-603	59.2	530
33	Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 1083-8	5.6	135
32	Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 732-5	5.6	52
31	Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 2576-9	5.6	52



30	Insulin-like growth factor-I in men with idiopathic osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 2799-805	5.6	150
29	Hypoparathyroidism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>1997</b> , 4, 427-432		9
28	Optimal dietary calcium intake in primary hyperparathyroidism. <i>American Journal of Medicine</i> , <b>1997</b> , 102, 543-50	2.4	45
27	Positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are associated with increases in the current, I(f), and the slope of the pacemaker potential. <i>Circulation</i> , <b>1997</b> , 96, 3704-9	16.7	38
26	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. <i>Journal of Bone and Mineral Research</i> , <b>1995</b> , 10, 1393-9	6.3	103
25	Release of guanosine triphosphate binding protein $\beta$ subunits from mouse myocardial membranes: Basic properties and their alterations in acute murine Chagas disease. <i>Cardiovascular Research</i> , <b>1995</b> , 29, 350-358	9.9	
24	Hypocalcemic Emergencies. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1993</b> , 22, 363-375	5.5	67
23	Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. <i>Journal of Bone and Mineral Research</i> , <b>1992</b> , 7, 913-9	6.3	110
22	Management of acute hypercalcemia. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 1196-203	59.2	227
21	Effects of guanine nucleotides and parathyroid hormone on inositol 1,4,5-trisphosphate metabolism in canine renal cortical tubular cell membranes. <i>Journal of Bone and Mineral Research</i> , <b>1991</b> , 6, 599-607	6.3	
20	Parathyroid hormone stimulates formation of inositol phosphates in a membrane preparation of canine renal cortical tubular cells. <i>Journal of Bone and Mineral Research</i> , <b>1990</b> , 5, 299-306	6.3	17
19	The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1990</b> , 70, 930-8	5.6	280
18	Skeletal disease in primary hyperparathyroidism. <i>Journal of Bone and Mineral Research</i> , <b>1989</b> , 4, 283-91	6.3	425
17	Stimulation of inositol phosphate formation in ROS 17/2.8 cell membranes by guanine nucleotide, calcium, and parathyroid hormone. <i>Journal of Bone and Mineral Research</i> , <b>1989</b> , 4, 413-20	6.3	34
16	Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. <i>American Journal of Medicine</i> , <b>1989</b> , 87, 553-7	2.4	98
15	Infection of L6E9 myoblasts with <i>Trypanosoma cruzi</i> alters adenylate cyclase activity and guanine nucleotide binding proteins. <i>Journal of Cellular Physiology</i> , <b>1987</b> , 133, 64-71	7	11
14	Enhancement of parathyroid hormone-responsive renal cortical adenylate cyclase activity by a cytosol protein activator from rat reticulocytes. <i>Journal of Bone and Mineral Research</i> , <b>1986</b> , 1, 41-50	6.3	1
13	The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. <i>Journal of Bone and Mineral Research</i> , <b>1986</b> , 1, 383-8	6.3	59

12	Modifications of the adenylate cyclase complex during differentiation of cultured myoblasts. <i>Journal of Cellular Physiology</i> , <b>1986</b> , 127, 28-38	7	14
11	The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. <i>New England Journal of Medicine</i> , <b>1984</b> , 310, 1221-5	59.2	223
10	Endothelial cells contain beta adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1984</b> , 325, 310-3	3.4	60
9	Reticulocyte cytosol activator protein: its actions upon the beta adrenergic receptor and the N-proteins of adenylate cyclase. <i>Journal of Receptors and Signal Transduction</i> , <b>1984</b> , 4, 475-86		1
8	Total and free propranolol levels in sensitive and resistant patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>1983</b> , 33, 163-71	6.1	8
7	Vitamin A toxicity and hypercalcemia. <i>American Journal of the Medical Sciences</i> , <b>1982</b> , 283, 161-4	2.2	45
6	A radioreceptor assay for propranolol and 4-hydroxypropranolol. <i>Clinical Pharmacology and Therapeutics</i> , <b>1980</b> , 28, 32-9	6.1	13
5	A radioreceptor assay for propranolol. <i>Clinical Pharmacology and Therapeutics</i> , <b>1979</b> , 26, 173-80	6.1	21
4	Bone Densitometry: The Best Way to Detect Osteoporosis and to Monitor Therapy		49
3	Approach to Parathyroid Disorders 535-542		
2	Combination Anabolic and Antiresorptive Therapy for Osteoporosis 444-447		
1	Chapter 66. Primary Hyperparathyroidism 301-306		1